Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2014

Open Access 01-12-2014 | Research

The clinical value of the quantitative detection of four cancer-testis antigen genes in multiple myeloma

Authors: Yao Zhang, Li Bao, Jin Lu, Kai-Yan Liu, Jin-Lan Li, Ya-Zhen Qin, Huan Chen, Ling-Di Li, Yuan Kong, Hong-Xia Shi, Yue-Yun Lai, Yan-Rong Liu, Bin Jiang, Shan-Shan Chen, Xiao-Jun Huang, Guo-Rui Ruan

Published in: Molecular Cancer | Issue 1/2014

Login to get access

Abstract

Background

Cancer-testis (CT) antigen genes might promote the progression of multiple myeloma (MM). CT antigens may act as diagnostic and prognostic markers in MM, but their expression levels and clinical implications in this disease are not fully understood. This study measured the expression levels of four CT antigen genes in Chinese patients with MM and explored their clinical implications.

Methods

Real-time quantitative polymerase chain reaction (qPCR) was used to quantify the expression of MAGE-C1/CT7, MAGE-A3, MAGE-C2/CT10 and SSX-2 mRNA in 256 bone marrow samples from 144 MM patients.

Results

In the newly diagnosed patients, the positive expression rates were 88.5% for MAGE-C1/CT7, 82.1% for MAGE-C2/CT10, 76.9% for MAGE-A3 and 25.6% for SSX-2. The expression levels and the number of co-expressed CT antigens correlated significantly with several clinical indicators, including the percentage of plasma cells infiltrating the bone marrow, abnormal chromosome karyotypes and the clinical course.

Conclusion

MAGE-C1/CT7, MAGE-A3, MAGE-C2/CT10 and SSX-2 expression levels provide potentially effective clinical indicators for the auxiliary diagnosis and monitoring of treatment efficacy in MM.
Appendix
Available only for authorised users
Literature
1.
Atanackovic D, Luetkens T, Hildebrandt Y, Arfsten J, Bartels K, Horn C, Stahl T, Cao Y, Zander AR, Bokemeyer C, Kröger N: Longitudinal analysis and prognostic effect of cancer-testis antigen expression in multiple myeloma. Clin Cancer Res. 2009, 15 (4): 1343-1352. 10.1158/1078-0432.CCR-08-0989CrossRefPubMed
2.
Meklat F, Li Z, Wang Z, Zhang Y, Zhang J, Jewell A, Lim SH: Cancer-testis antigens in haematological malignancies. Br J Haematol. 2007, 136 (6): 769-776. 10.1111/j.1365-2141.2006.06484.xCrossRefPubMed
3.
Atanackovic D, Hildebrandt Y, Jadczak A, Cao Y, Luetkens T, Meyer S, Kobold S, Bartels K, Pabst C, Lajmi N, Gordic M, Stahl T, Zander AR, Bokemeyer C, Kröger N: Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells. Haematologica. 2010, 95 (5): 785-793. 10.3324/haematol.2009.014464PubMedCentralCrossRefPubMed
4.
Perez D, Herrmann T, Jungbluth AA, Samartzis P, Spagnoli G, Demartines N, Clavien PA, Marino S, Seifert B, Jaeger D: Cancer testis antigen expression in gastrointestinal stromal tumors: new markers for early recurrence. Int J Cancer. 2008, 123: 1551-1555. 10.1002/ijc.23698CrossRefPubMed
5.
Güre AO, Stockert E, Arden KC, Boyer AD, Viars CS, Scanlan MJ, Old LJ, Chen YT: CT10: A new cancer-testis (CT) antigen homologous to CT7 and the MAGE family, identified by refresentational-difference analysis. Int J Cancer. 2000, 85: 726-732. 10.1002/(SICI)1097-0215(20000301)85:5<726::AID-IJC21>3.0.CO;2-FCrossRefPubMed
6.
Jungbluth AA, Chen YT, Busam KJ, Coplan K, Kolb D, Iversen K, Williamson B, Van Landeghem FK, Stockert E, Old LJ: CT7 (MAGE-C1) antigen expression in normal and neoplastic tissues. Int J Cancer. 2002, 99: 839-845. 10.1002/ijc.10416CrossRefPubMed
7.
Atanackovic D, Arfsten J, Cao Y, Gnjatic S, Schnieders F, Bartels K, Schilling G, Faltz C, Wolschke C, Dierlamm J, Ritter G, Eiermann T, Hossfeld DK, Zander AR, Jungbluth AA, Old LJ, Bokemeyer C, Kröger N: Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. Blood. 2007, 109: 1103-1112.CrossRefPubMed
8.
Pastorcic-Grgic M, Sarcevic B, Dosen D, Juretic A, Spagnoli GC, Grgic M: Prognostic value of MAGE-A and NY-ESO-1 expression in pharyngeal cancer. Head Neck. 2010, 32: 1178-1184. 10.1002/hed.21314CrossRefPubMed
9.
Shigematsu Y, Hanagiri T, Shiota H, Kuroda K, Baba T, Mizukami M, So T, Ichiki Y, Yasuda M, So T, Takenoyama M, Yasumoto K: Clinical significance of cancer/testis antigens expression in patients with non-small cell lung cancer. Lung cancer. 2010, 68: 105-110. 10.1016/j.lungcan.2009.05.010CrossRefPubMed
10.
Cumova J, Potacova A, Zdrahal Z, Hajek R: Proteomic Analysis in Multiple Myeloma Research. Mol Biotechnol. 2011, 47: 83-93. 10.1007/s12033-010-9326-xCrossRefPubMed
11.
Condomines M, Hose D, Raynaud P, Hundemer M, De Vos J, Baudard M, Moehler T, Pantesco V, Moos M, Schved JF, Rossi JF, Rème T, Goldschmidt H, Klein B: Cancer/testis genes in multiple myeloma: expression patterns and prognosis value determined by microarray analysis. J Immunol. 2007, 178: 3307-3315.CrossRefPubMed
12.
Van Duin M, Broyl A, De Knegt Y, Goldschmidt H, Richardson PG, Hop WC, van der Holt B, Joseph-Pietras D, Mulligan G, Neuwirth R, Sahota SS, Sonneveld P: Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy. Haematologica. 2011, 96 (11): 1662-1669. 10.3324/haematol.2010.037978PubMedCentralCrossRefPubMed
13.
Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK, Morgan G, Van Ness B, Chesi M, Minvielle S, Neri A, Barlogie B, Kuehl WM, Liebisch P, Davies F, Chen-Kiang S, Durie BG, Carrasco R, Sezer O, Reiman T, Pilarski L, Avet-Loiseau H: International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia. 2009, 23: 2210-2221. 10.1038/leu.2009.174PubMedCentralCrossRefPubMed
14.
Riener MO, Wild PJ, Soll C, Knuth A, Jin B, Jungbluth A, Hellerbrand C, Clavien PA, Moch H, Jochum W: Frequent expression of the novel cancer testis antigen MAGE-C2/CT-10 in hepatocellular carcinoma. Int J Cancer. 2009, 124: 352-357. 10.1002/ijc.23966CrossRefPubMed
15.
Jungbluth AA, Ely S, DiLiberto M, Niesvizky R, Williamson B, Frosina D, Chen YT, Bhardwaj N, Chen-Kiang S, Old LJ, Cho HJ: The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. Blood. 2005, 106 (1): 167-174. 10.1182/blood-2004-12-4931CrossRefPubMed
16.
Pabst C, Zustin J, Jacobsen F, Luetkens T, Kröger N, Schilling G, Bokemeyer C, Sauter G, Atanackovic D, Marx A: Expression and prognostic relevance of MAGE-C1/CT7 and MAGE-C2/CT10 in osteolytic lesions of patients with multiple myeloma. Exp Mol Pathol. 2010, 89 (2): 175-181. 10.1016/j.yexmp.2010.06.011CrossRefPubMed
17.
Taylor BJ, Reiman T, Pittman JA, Keats JJ, De Bruijn DR, Mant MJ, Belch AR, Pilarski LM: SSX cancer testis antigens are expressed in most multiple myeloma patients: co-expression of SSX1, 2, 4, and 5 correlates with adverse prognosis and high frequencies of SSX-positive PCs. J Immunother. 2005, 28 (6): 564-575. 10.1097/01.cji.0000175685.36239.e5CrossRefPubMed
18.
Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J: International Staging System for Multiple Myeloma. J Clin Oncol. 2005, 15: 3412-3420.CrossRef
19.
Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV: International uniform response criteria for multiple myeloma. Leukemia. 2006, 20: 1467-1473. 10.1038/sj.leu.2404284CrossRefPubMed
20.
Ruan GR, Qin YZ, Chen SS, Li JL, Ma X, Chang Y, Wang YZ, Fu JY, Liu YR: Abnormal expression of the programmed cell death 5 gene in acute and chronic myeloid leukemia. Leuk Res. 2006, 30 (9): 1159-1165. 10.1016/j.leukres.2005.12.028CrossRefPubMed
21.
Niu J, Li H, Zhang Y, Li J, Xie M, Li L, Qin X, Qin Y, Guo X, Jiang Q, Liu Y, Chen S, Huang X, Han W, Ruan G: Aberrant expression of CKLF-like MARVEL transmembrane member 5 (CMTM5) by promoter methylation in myeloid leukemia. Leuk Res. 2011, 35: 771-776. 10.1016/j.leukres.2010.11.023CrossRefPubMed
22.
Beillard E, Pallisgaard N, van der Velden VH, Bi W, Dee R, van der Schoot E, Delabesse E, Macintyre E, Gottardi E, Saglio G, Watzinger F, Lion T, Van Dongen JJ, Hokland P, Gabert J: Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) – a Europe against cancer program. Leukemia. 2003, 17: 2474-2486. 10.1038/sj.leu.2403136CrossRefPubMed
23.
van der Velden VH, Hochhaus A, Cazzaniga G, Szczepanski T, Gabert J, Van Dongen JJ: Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia. 2003, 17: 1013-1034. 10.1038/sj.leu.2402922CrossRefPubMed
24.
Liu YR, Yu H, Chang Y, Chen SS: The application of 4-color fluorescence labeling antibodies and its significance in immunophenotyping for leukemia by flow cytometer. Zhong guo Shi Yan Xue Ye Xue Za Zhi. 2003, 10: 423-427.
25.
Zhang Y, He Q, Huang XJ, Jiang H, Yang SM, Lu J, Qing YZ, Shi Y, Dang H, Qiu JY, Lu DP: Cytogenetic study on eosinophilia. Zhong guo Shi Yan Xue Ye Xue Za Zhi. 2007, 15: 454-457.
Metadata
Title
The clinical value of the quantitative detection of four cancer-testis antigen genes in multiple myeloma
Authors
Yao Zhang
Li Bao
Jin Lu
Kai-Yan Liu
Jin-Lan Li
Ya-Zhen Qin
Huan Chen
Ling-Di Li
Yuan Kong
Hong-Xia Shi
Yue-Yun Lai
Yan-Rong Liu
Bin Jiang
Shan-Shan Chen
Xiao-Jun Huang
Guo-Rui Ruan
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2014
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-13-25

Other articles of this Issue 1/2014

Molecular Cancer 1/2014 Go to the issue

Research

SOX1 down-regulates β-catenin and reverses malignant phenotype in nasopharyngeal carcinoma

Research

Autophagic flux determines cell death and survival in response to Apo2L/TRAIL (dulanermin)

Research

The role of high cell density in the promotion of neuroendocrine transdifferentiation of prostate cancer cells

Research

Critical role of histone demethylase RBP2 in human gastric cancer angiogenesis

Research

Trop-2-targeting tetrakis-ranpirnase has potent antitumor activity against triple-negative breast cancer

Research

DTX3L and ARTD9 inhibit IRF1 expression and mediate in cooperation with ARTD8 survival and proliferation of metastatic prostate cancer cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits